# IDeate-Lung01 (NCT05280470)

> Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05280470
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Extensive-stage Small-cell Lung Cancer
- Interventions: Ifinatamab Deruxtecan (I-DXd)
- Enrollment: 187
- Primary outcome: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC

## Commentary we found

- X threads: 17
- YouTube: 4
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=ideate-lung01-nct05280470

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05280470", "email": "<work email>"}; the inbox owner confirms by the emailed link.